Spinal Stenosis Clinical Trial
Official title:
A Study To Evaluate The Safety And Effectiveness Of TOPS™ System In The Lumbar Spine
This Single-Arm Post-Marketing Evaluation will gauge the improvement in function and pain for lumbar spinal stenosis and spondylolisthesis patients with the TOPS System.
Status | Recruiting |
Enrollment | 10 |
Est. completion date | December 2016 |
Est. primary completion date | December 2016 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 40 Years to 85 Years |
Eligibility |
Inclusion Criteria: Any subject meeting the following criteria will be considered for inclusion in this trial. 1. Patients with one or both of the following conditions at a single spinal level between L3 and L5 are eligible for the TOPS™ System: - Symptomatic monosegmental lumbar spinal stenosis or facet arthrosis - Degenerative Spondylolisthesis up to and including grade 1 2. At least three (3) months of failed, conservative treatment, including use of anti-inflammatory medications at maximum specified dosage; epidural/facet injections, unless deemed inadvisable due to progressive motor weakness or other evidence of deteriorating condition; rest, heat, electrotherapy/physical therapy; 3. Moderate to Severe narrowing of the lumbar spinal canal identified on CT /MRI scans 4. Age 40-85 years old 5. Lower back pain /sciatica with or without spinal claudication 6. Psychosocially, mentally and physically able to fully comply with the clinical protocol and willing to adhere to the follow-up schedule. 7. VAS leg pain of at least 40/100 at baseline. 8. Oswestry Questionnaire score of at least 40/100 at baseline Exclusion Criteria: Patients who meet any of the following conditions or criteria are excluded from this study: 1. Primary diagnosis of discogenic back pain at the TOPS System level 2. Back or non-radicular leg pain of unknown etiology at the TOPS System level 3. Lytic spondylolisthesis at the TOPS System level 4. More than one (1) motion segment involved in the degenerative pathology to the extent that justifies its inclusion in the surgical procedure, unless a decompression alone can be done at that level without compromising stability. 5. Known allergy to titanium and/or polyurethane 6. Prior surgery at any lumbar vertebral level. 7. Supplemental interbody support required (e.g., VBRs, or fusion cages) at the TOPS System level 8. Clinically compromised vertebral bodies at the affected level(s) due to any traumatic, neoplastic, metabolic or infectious pathology. 9. Deformity of the spine that would compromise the implant, e.g. scoliosis of greater than ten (10) degrees 10. Morbid obesity (a body mass index > 40) or a weight more than 100 lbs. over ideal body weight. 11. DEXA bone density T score equal to or lower than - 2.0 12. Paget's disease, osteomalacia, osteogenesis imperfecta, thyroid and/or parathyroid gland disorder and/or any other metabolic bone disease. 13. Active infection - systemic or local 14. AIDS, HIV, or active hepatitis 15. Rheumatoid arthritis or other autoimmune disease. 16. Tuberculosis active or in the past 3 years. 17. Active malignancy: A patient with a history of any invasive malignancy (except non-melanoma skin cancer), unless he/she has been treated with curative intent and there have been no clinical signs or symptoms of the malignancy for at least 5 years. 18. Medical conditions requiring treatment with any drugs known to potentially interfere with bone/soft tissue healing 19. Pregnant or interested in becoming pregnant in the next 3 years. 20. Current chemical/alcohol dependency or psychosocial disturbance. 21. Cauda equina syndrome or neurogenic bowel/bladder dysfunction 22. Severe arterial insufficiency of the legs, peripheral vascular disease 23. Sustained pathologic fractures of the vertebra or multiple fractures of the vertebra or hip 24. Unremitting pain in any spinal position 25. Significant peripheral neuropathy 26. Immunologically suppressed, received steroids > 1 month out of the past year aa. Insulin-dependent diabetes mellitus bb. Currently taking anticoagulants other than aspirin (e.g., Plavix) cc. Life expectancy less than 3 years dd. Waddell signs > 3 ee. Currently involved in active spinal litigation ff. Subject is incarcerated |
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United Kingdom | University Hospital Southampton NHS Foundation Trust | Southampton |
Lead Sponsor | Collaborator |
---|---|
Premia Spine |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | VAS (Visual Analog Score) | Pain assessment | 2 YEARS | No |
Secondary | SF-36 (Short-Form) | Quality of life | 2 YEARS | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT06290908 -
RPE-P/TLIF for Lumbar Spinal Stenosis With Instability
|
||
Withdrawn |
NCT03223701 -
Efficacy of Using Solum IV and BMC With GFC in TLIF
|
Phase 4 | |
Recruiting |
NCT03883022 -
Vancomycin Powder Combined With Autogenous Bone Graft as a Prevention for Post-operative Infection for Spine Surgery
|
N/A | |
Completed |
NCT02902380 -
The Effect of Dexmedetomidine on Neuroendocrine Stress Hormone Release and Heart Rate Variability in Patients Undergoing Major Spinal Surgery
|
N/A | |
Not yet recruiting |
NCT06024785 -
Vertebropexy - Randomized-controlled Trial
|
N/A | |
Not yet recruiting |
NCT06000319 -
Natural Matrix Protein™ (NMP™) Fibers in Cervical and Lumbar Interbody Fusion
|
||
Completed |
NCT02558621 -
New Robotic Assistance System for Spinal Fusion Surgery
|
N/A | |
Completed |
NCT02454400 -
Pre-surgery Physiotherapy for Patients With Specific Low Back Pain
|
N/A | |
Completed |
NCT01377623 -
Pilot Study on the Effect of Dexmedetomidine on Inflammatory Responses in Patients Undergoing Lumbar Spinal Fusion
|
N/A | |
Completed |
NCT00996073 -
Safety and Preliminary Efficacy Study of NeoFuse in Subjects Requiring Lumbar Interbody Fusion
|
Phase 2 | |
Terminated |
NCT00974623 -
Bone Graft Materials Observational Registry
|
N/A | |
Completed |
NCT00022776 -
Surgical Versus Nonsurgical Treatment for Spinal Stenosis
|
Phase 3 | |
Completed |
NCT00320619 -
Epsilon-Aminocaproaic Acid to Reduce the Need for Blood Transfusions During and Following Spine Surgery
|
N/A | |
Completed |
NCT06060821 -
Validity and Reliability of the 2-minute Step Test in Patients With Lumbar Spinal Stenosis
|
||
Recruiting |
NCT04552145 -
Physical Therapy vs Surgical Decompression for Lumbar Spinal Stenosis
|
N/A | |
Active, not recruiting |
NCT04379921 -
Improving Spine Surgical Care With Real-Time Objective Patient Tracking Using the Apple Watch
|
N/A | |
Withdrawn |
NCT04315090 -
Post-surgical Outcomes Measure Using the ERAS Protocol for Posterior Cervical Decompression and Fusion
|
||
Completed |
NCT04591249 -
Physical Activity Intervention for Patients Following Lumbar Spine Surgery
|
N/A | |
Recruiting |
NCT04601363 -
Personalized Spine Study Group (PSSG) Registry
|
||
Completed |
NCT04193488 -
Mid-Transverse Process to Pleural (MTP) Block and Erector Spinal Plan (ESP) Block in Spinal Surgery
|
N/A |